TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock



Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	2,397,956,000,000		2,593,642,000,000		2,712,893,000,000	
Common stock capital		1,676,345,000,000		1,676,263,000,000		1,668,145,000,000
Fixed assets	11,559,794,000,000		10,584,376,000,000		10,199,400,000,000	
Equity capital of a company		6,354,671,000,000		5,683,523,000,000		5,177,177,000,000
Cash and cash equivalents	229,557,000,000		849,695,000,000		966,222,000,000	
Accrued liabilities		183,563,000,000		198,046,000,000		197,605,000,000
Other assets	-		-		-	
Current liabilities		2,481,940,000,000		2,145,730,000,000		1,773,176,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,121,140,000,000		5,348,766,000,000		5,961,940,000,000
Different income		-		-		-
Other liabilities		204,488,000,000		146,430,000,000		222,040,000,000
Total assets	13,957,750,000,000	13,957,750,000,000	13,178,018,000,000	13,178,018,000,000	12,912,293,000,000	12,912,293,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	49,095	47,347	47,099
Equity ratio	45.53%	43.13%	40.13%
Debt-equity ratio	119.63%	131.84%	149.21%

Others

	2023	2022	2021
Tax Expense Rate	15.13%	22.77%	-2.71%

TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock

Income statement

	0000	0000	0004
	2023	2022	2021
Turnover	4,027,478,000,000	3,569,006,000,000	3,197,812,000,000
Net income	317,017,000,000	230,059,000,000	376,005,000,000
EBIT	3,087,636,000	2,730,468,000	3,072,534,000
Operating income before taxes	383,720,000,000	317,938,000,000	366,159,000,000
Cash Flow	877,217,000,000	1,021,218,000,000	905,073,000,000
Net interest income	-130,886,000,000	-137,140,000,000	-145,930,000,000
Research and development expenses	633,325,000,000	526,087,000,000	455,765,000,000
Income taxes	58,052,000,000	72,405,000,000	-9,936,000,000
Result from investments in subsidaries, associates and other	-8,630,000,000	-15,367,000,000	76,000,000
Revenues per employee	492,206	452,279	407,373

Board of Directors

Masami lijima	Chairman of Supervisory Board
Andrew Plump	Member of Supervisory Board
John Maraganore	Member of Supervisory Board
Olivier Jean Bohuon	Member of Supervisory Board
Steven Gillis	Member of Supervisory Board
Constantine Saroukos	Member of Supervisory Board
Emiko Higashi	Member of Supervisory Board
lan Clark	Member of Supervisory Board
Jean-Luc Butel	Member of Supervisory Board
Kimberly Reed	Member of Supervisory Board
Koji Hatsukawa	Member of Supervisory Board
Michel Orsinger	Member of Supervisory Board
Miki Tsusaka	Member of Supervisory Board
Yoshiaki Fujimori	Member of Supervisory Board

Members of Management Board

Christophe Weber	Chairman of Managing Board
Andrew Plump	Member of Executive Committee
Costa Saroukos	Member of Executive Committee
Gabriele Ricci	Member of Executive Committee
Giles Platford	Member of Executive Committee
Julie Kim	Member of Executive Committee
Koki Sato	Member of Executive Committee
Lauren Duprey	Member of Executive Committee
Marcello Agosti	Member of Executive Committee
Milano Furuta	Member of Executive Committee
Mwana Lugogo	Member of Executive Committee
Ramona Sequeira	Member of Executive Committee
Takako Ohyabu	Member of Executive Committee
Teresa Bitetti	Member of Executive Committee
Thomas Wozniewski	Member of Executive Committee
Yoshihiro Nakagawa	Member of Executive Committee